Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660985 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
A Phase 4 study of Acne Vulgaris, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT00660985 is a Phase 4 study of Acne Vulgaris that has completed, run by Galderma R&D. The registered enrollment target is 51 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00660985, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.
Conditions Studied
Interventions
- DRUG Adapalene
Study Locations (2)
Texas
- DermResearch, Inc. - Austin
- J&S Studies, Inc. - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660985
The ClinicalTrials.gov registry entry for NCT00660985 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (81% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Adapalene is the first listed.
NCT00660985 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00660985 about?
NCT00660985 is a clinical study titled "Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%". Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.
What is the current status of trial NCT00660985?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2008-05. Estimated completion is 2008-11.
What conditions does trial NCT00660985 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT00660985?
The interventions under investigation include: Adapalene (DRUG).
Who is sponsoring clinical trial NCT00660985?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00660985 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
-
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 4
-
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
COMPLETED · Phase 4
-
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
COMPLETED · Phase 4
-
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
COMPLETED · Phase 4
-
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.